- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Utility of Genomic Testing
New genomic tests continue to be introduced, and in this segment, Peter Salgo, MD, and John L. Fox, MD, MHA, discuss the clinical utility of genomic tests and explore data from key trials that evaluated the validity of current genomic tests.
Dr Fox explains that when reviewing clinical utility it is important to assess whether or not the new information has an impact on decision making and overall clinical outcomes. Dr Fox adds that the MammaPrint, OncoType DX, and PAM50 genomic assays have all demonstrated clinical utility in breast cancer. When asked about the validity of a newer breast cancer assay, Prosigna, Dr Fox discusses the TransATAC trial and explains that results are inconclusive due to a stratification advantage.
Ultimately, all stakeholders involved in patient care want to have a clear understanding of available diagnostic tests. The goal is to use the test results to make informed decisions and allow each patient to receive the treatment that is most appropriate for his or her condition.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
